Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

被引：33

作者：

Kuppen, Malou C. P. ^{[1
]}

Westgeest, Hans M. ^{[2
]}

van der Doelen, Maarten J. ^{[3
]}

van den Eertwegh, Alphonsus J. M. ^{[4
]}

Coenen, Jules L. L. M. ^{[5
]}

Aben, Katja K. H. ^{[6
,7
]}

van den Bergh, Alphons C. M. ^{[8
]}

Bergman, Andries M. ^{[9
]}

van den Bosch, Joan ^{[10
]}

Celik, Filiz ^{[11
]}

Hendriks, Mathijs P. ^{[12
]}

Lavalaye, Jules ^{[13
]}

van der Meer, Saskia ^{[14
]}

Polee, Marco B. ^{[15
]}

Somford, Diederik M. ^{[16
]}

van Oort, Inge M. ^{[17
]}

Uyl-de Groot, Carin A. ^{[1
]}

Gerritsen, Winald R. ^{[3
]}

机构：

[1] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Inst Med Technol Assessment, Rotterdam, Netherlands

[2] Amphia Hosp, Dept Internal Med, Breda, Netherlands

[3] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Nijmegen, Netherlands

[4] Vrije Univ, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam UMC, Amsterdam, Netherlands

[5] Isala, Dept Oncol, Zwolle, Netherlands

[6] Radboud Univ Nijmegen, Dept Hlth Evidence, Med Ctr, Nijmegen, Netherlands

[7] Netherlands Comprehens Canc Org, Utrecht, Netherlands

[8] Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands

[9] Netherlands Canc Inst, Div Internal Med MOD & Oncogen, Antoni van Leeuwenhoek Hosp, Amsterdam, Netherlands

[10] Albert Schweitzer Ziekenhuis, Dept Internal Med, Dordrecht, Netherlands

[11] Deventer Hosp, Dept Nucl Med, Deventer, Netherlands

[12] Northwest Clin, Dept Internal Med, Alkmaar, Netherlands

[13] St Antonius Hosp, Dept Nucl Med, Nieuwegein, Netherlands

[14] Jeroen Bosch Hosp, Dept Urol, sHertogenbosch, Netherlands

[15] Med Ctr Leeuwarden, Dept Internal Med, Leeuwarden, Netherlands

[16] Canisius Wilhelmina Hosp, Dept Urol, Nijmegen, Netherlands

[17] Radboud Univ Nijmegen, Dept Urol, Med Ctr, Nijmegen, Netherlands

来源：

FUTURE ONCOLOGY | 2020年 / 16卷 / 19期

关键词：

metastatic castration-resistant prostate cancer; radium-223; real-world outcomes; sequencing; skeletal-related events; survival; BONE METASTASES; DOUBLE-BLIND; THERAPY; PHASE-3; TRIAL; RECOMMENDATIONS; EXPERIENCE; EFFICACY; EVENTS; CYCLES;

D O I：

10.2217/fon-2020-0039

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line >= 3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line >= 3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.

引用

页码：1371 / 1384

页数：14

共 50 条

[31] Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases
Vogelzang, Nicholas J.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (08) : 809 - 819
[32] Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer
Borso, Elisa
Boni, Giuseppe
Galli, Luca
Ricci, Sergio
Farnesi, Azzurra
Mazzarri, Sara
Cianci, Claudia
Mariani, Giuliano
Falcone, Alfredo
FUTURE ONCOLOGY, 2015, 11 (02) : 323 - 331
[33] Real-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): Results from the Dutch CAPRI registry
Kuppen, M. C. P.
Westgeest, H. M.
van den Eertwegh, A. J. M.
Van Moorselaar, J.
Mehra, N.
Coenen, J. L.
van Oort, I.
van den Bergh, A. C. M.
Lavalaye, J.
Aben, K. K. H.
Somford, D. M.
de Wit, R.
Bergman, A. M.
Uyl-de Groot, C.
Gerritsen, W. R.
ANNALS OF ONCOLOGY, 2019, 30
[34] REAL-WORLD TREATMENT PATTERNS OF RADIUM-223 IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER RECEIVING CARE AT A US TERTIARY ONCOLOGY CENTER
McKay, R. R.
Silver, R.
Bhak, R.
Korves, C.
Cheng, W. Y.
Chang, R.
Appukkuttan, S.
Simmons, S. J.
Duh, M. S.
Taplin, M. E.
VALUE IN HEALTH, 2020, 23 : S28 - S28
[35] Radium-223 for metastatic, castration- resistant prostate cancer: A retrospective chart review study of real-world use in a tertiary hospital in Taiwan
Weng, Wei -Chun
Huang, Li-Hua
Tseng, Neng-Chuan
Ou, Yen-Chuan
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (10) : 1929 - 1937
[36] Radium-223 for the treatment of castration-resistant prostate cancer
El-Amm, Joelle
Aragon-Ching, Jeanny B.
ONCOTARGETS AND THERAPY, 2015, 8 : 1103 - 1109
[37] Metastatic castration resistant prostate cancer patients' experience with Radium-223 treatment in Japan
Akakura, Koichiro
Uemura, Hiroji
Kawakami, Satoru
Yokomizo, Akira
Nakamura, Motonobu
Nishimura, Kazuo
Komori, Tetsushi
Ledesma, Dianne Athene
FUTURE ONCOLOGY, 2024, 20 (12) : 781 - 798
[38] Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Yong Du
Ignasi Carrio
Giuseppe De Vincentis
Stefano Fanti
Harun Ilhan
Caroline Mommsen
Egbert Nitzsche
Francis Sundram
Wouter Vogel
Wim Oyen
Val Lewington
European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1671 - 1678
[39] Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold
Aprile, Carlo
Persico, Marco G.
Lodola, Lorenzo
Buroni, Federica E.
WORLD JOURNAL OF RADIOLOGY, 2016, 8 (10): : 816 - 818
[40] Radium-223 for the treatment of metastatic castration-resistant prostate cancer: A window of opportunity
Gomez-Veiga, F.
Alvarez-Ossorio, J. L.
Carballido-Rodriguez, J.
Juarez-Soto, A.
Rodriguez-Antolin, A.
Cozar-Olmo, J. M.
ACTAS UROLOGICAS ESPANOLAS, 2018, 42 (10): : 616 - 624

← 1 2 3 4 5 →